iiinova — where your digital self keeps evolving

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

13/13 There are so many people to thank for their contributions to this work. Most importantly my advisor Adam Palmer. I'd also like to thank @unclineberger.bsky.social and @unc-phco.bsky.social (and a lot of other individuals and organizations not on bluesky).

020

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

12/n This model provides quantitative insight into how combination therapy can overcome heterogeneity within and between tumors to cure many patients with Large B-Cell Lymphoma. We hope it is a practical tool to explore new combinations based on clinical data on new drugs.

110

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

10/n Looking at ‘RCHOP+X’ trials, we used clinical data on each ‘drug X’ to predict the clinical trial results. Only Pola-R-CHP, and Tucidinostat + R-CHOP, were expected to succeed, and indeed they did www.asco.org/abstracts-presentations/ABSTRACT451754 www.nejm.org/doi/full/10.1056/NEJMoa2115304

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

9/n We calibrated the model to reproduce Progression-Free Survival for the CHOP and RCHOP regimens for Diffuse Large B-Cell Lymphoma. Simulated tumor population shrinkage agreed well with observed changes in circulating tumor DNA after the first cycle of RCHOP:

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

8/n From this ‘bottom-up’ model of tumor heterogeneity, simulating treatment responses in a cohort of patients produces a Kaplan-Meier curve of Progression-Free Survival:

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

7/n This extends to combination therapy by using a different dimension of heterogeneity for each drug This way, patients and cells vary in their sensitivity to different drugs; for example, some patients can be more sensitive to one drug than another, or sensitive to both, etc.

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

6/n Extending to patient variability, a group of patients - say in a clinical trial - also have a distribution of drug response phenotypes, with each patient’s cancer containing a range of cellular heterogeneity around the average drug sensitivity of that individual.

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

5/n In this model of heterogeneity as a distribution of states, each cycle of chemotherapy progressively shifts the distribution to increasingly drug-resistant states

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

4/n Many insightful models of tumor heterogeneity described drug-sensitive and drug-resistant subpopulations. Based on clone-tracing, we modelled cellular heterogeneity as a distribution of sensitivity phenotypes, reflecting many complex influences on drug response

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

3/n We built a model that unifies intra-tumor and inter-patient heterogeneity in drug sensitivity to understand the clinical efficacy of curative-intent combination therapy for Large B-Cell Lymphoma.

100

Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025

2/n Cell-to-cell and patient-to-patient heterogeneity both have a role in the success of drug combinations. While inter-patient variation can explain better response rates of combos for incurable cancers, CURES need a regimen to overcome cellular heterogeneity and evolution.

130

Reposted by Amy Pomeroy

Association for Cancer Systems Biologists @cancersysbio.bsky.social · 10/02/2025

An impressive result from their work - their model would have been able to predict from single treatment trials what would have happened in the combination trials

011

Reposted by Amy Pomeroy

Association for Cancer Systems Biologists @cancersysbio.bsky.social · 10/02/2025

Dr. Amy Pomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy doi.org/10.1101/2024...

132